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Abstract: Cognitive psychology has provided clinicians with specific tools for analyzing the
processes of cognition (memory, language) and executive functions (attention-concentration, abstract
reasoning, planning). Neuropsychology, coupled with the neurosciences (including neuroimaging
techniques), has authenticated the existence of early disorders affecting the “superior or intellectual”
functions of the human brain. The prevalence of cognitive and attention disorders is high in adults
because all the diseases implicating the central nervous system are associated with cognitive
correlates of variable intensity depending on the disease process and the age of the patient. In some
pathologies, cognitive impairment can be a leading symptom such as in schizophrenia, posttraumatic
stress disorder or an emblematic stigmata as in dementia including Alzheimer’s disease.
Paradoxically, public health authorities have only recognized as medications for improving cognitive
symptoms those with proven efficacy in the symptomatic treatment of patients with Alzheimer’s
disease; the other cognitive impairments are relegated to the orphanage of syndromes and symptoms
dispossessed of medication. The purpose of this review is to promote a true “pharmacology of
cognition” based on the recent knowledge in neurosciences. Data from adult human beings, mainly
concerning memory, language, and attention processes, will be reported. “Drug therapeutic
strategies” for improving cognition (except for memory function) are currently rather scarce, but
promising perspectives for a new neurobiological approach to cognitive pharmacology will be
highlighted.
Keywords: cognitive disorders, attention, memory, pharmacology, treatment, pharmacovigilance,
dementia.
Introduction
In human beings, cognitive functions correspond schematically to the brain processes
of acquisition and exploitation of knowledge. Research in cognitive psychology and
neurosciences is devoted to unraveling these complex processes that underlie several
mental functions. The focus has been put on the analysis of what used to be called
“superior functions” such as language, memory or decision-making because of their
important role in thought and communication between individuals. The high
prevalence of cognitive complaints has prompted neuropsychologists to elaborate
tools necessary for the objective measurement and understanding of cognitive
alterations, thereby allowing the establishment of a diagnosis. Thus, in the clinical
setting, cognitive impairment corresponds to a symptom (eg, amnesia), a combination
of symptoms defining a recognized syndrome (eg, amnesic syndrome) or a specific
disease (eg, Alzheimer’s disease [AD]). Each nosographic entity is described by a set of
criteria defining alterations in memory (Tulving 1985; De Deyn et al 2003; Lieury
2005), language (Damasio and Damasio 1992; Damasio et al 1996; Damasio 1997;
Frederici 2000; Fries et al 2003), and executive functions, which also include
concentration, or more precisely attention (Berger and Posner 2000; Cowan et al 2005)
necessary for planning, organization, and synchronization of complex actions (Stuss
et al 1995; Stuss and Alexander 2000; Royall et al 2002).Neuropsychiatric Disease and Treatment 2007:3(1) 104
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Cognitive impairment, explicitly demonstrated by altered
performance in specific tasks, is of high prevalence as it is
associated with advanced age (Raz 2000) and most
neurological and psychiatric disorders. As a rule, the
impairment affects several domains of cognition (memories,
executive functions, attention, etc) simultaneously or
consecutively (eg, isolated memory impairment converting
into AD). It can develop progressively (neurodegenerative
diseases) or occur suddenly after an acute event (stroke, head
trauma).
The severity of the cognitive impairment is often in the
forefront of a major clinical presentation like in dementia
(Geschwind et al 2001; Pachana et al 1996), Attention-
Deficit-Hyperactivity Disorder (ADHD) (Elia et al 1999),
schizophrenia (Kuperberg and Heckers 2000; Aleman et al
1999; Heinrichs and Zakzanis 1998), or Parkinson’s disease
(PD) (Boyle et al 2005; Fernandez et al 2005). Cognitive
impairment thus occurs in very different contexts involving
the central nervous system (CNS) and resulting from very
different pathogenic processes (neurodegeneration,
inflammation, toxic reaction, ischemia, trauma, neurochemical
deficiency) (Budson and Price 2005). This has logically led
to a new domain of pharmaceutical research, “cognitive
pharmacology”, and, with recent advances in neurobiology,
the emergence of new therapeutic perspectives for improving
altered cognitive functions (Table 1).
Table 1  Main cognitive disorders
Orientation
Attention/Concentration/Distractibility
Overload-Breakdown of comprehension
Memories
Reasoning and problem solving
Organizational skills
Rate of processing
Perseverance
Motivation/initiation
The purpose of this review is to highlight potential drugs,
and therefore therapeutic drug strategies for improving
cognitive impairment in adults. Arguments are also put forward
favoring more extensive indications for pharmacological
management of a wider range of pathological conditions
involving cognitive dysfunction; this will broaden the
scope of patients benefiting from advances in cognitive
pharmacology and neurosciences, as strongly suggested by
the 2nd Canadian Conference on Antidementia Drugs
(Feldman et al 2006).
The biological basis of cognition
Although the biological and neurochemical basis of human
cognition is undeniable (Ichols and Newsome 1999), human
thought is something more than the result of a chemical
secretion of the brain. Cognition is a complex phenomenon
involving multiple levels of neurobiological processes. Very
schematically, studies are thus designed to search for a
correlation between a given task requiring cognitive work
and an observable elementary change within the CNS. Access
to specific modules of cognition, particularly memory (Lynch
2002; Arshavsky 2003; Drapeau et al 2003; Nader 2003) and
attention (Coull 1998; Filley 2002; Russell et al 2005), can
be facilitated with animal models, mainly in rodents and
primates, whereas language and linguistics are strictly limited
to human research (Perani et al 1999; Pulvermuller 1999).
Functional anatomy
Functional neuroimaging using positron emission tomography
(PET), functional nuclear magnetic resonance (fMRI),
magnetoencephalography (MEG) or magnetic resonance
spectroscopy (Ross and Sachdev 2004) has greatly
contributed to our knowledge of the anatomic substrate of
the principal cognitive functions. The hippocampus is
involved in detecting and encoding new information and
the striato-frontal circuits in decision making processes while
the frontal lobe is involved the contextual retrieval and in
the shift from one idea or one task to another. Long-term
memory and its storage are scattered over different areas of
the cerebral cortex (Woolf 1998); this notion of distributed
anatomic localizations contrasts with the localized areas
described by phrenology. A bilingual person, for example,
has distinct and separate temporal cortical areas handling
each separate language, passage from one to the other
activating the Broca area and spelling and phonology
activating the supramarginalis gyrus (Price et al 1999).
Attentional processes also involve a substratum of complex
networks regulating and maintaining alertness and
orienting sensorial information and executive control (Fan
and Posner 2004; Filley 2002; Fernandez-Duque and
Posner 2001).
Knowledge of the functional substratum in the human
brain is particularly important in neuropsychology. Zhang
and Feng (1999) reported particularly illustrative work
demonstrating that analysis of Chinese characters with their
fundamental attributes (pictographic similarity, homophony,
synonymia) involves close collaboration between the two
cerebral hemispheres, probably via the corpus callosum.Neuropsychiatric Disease and Treatment 2007:3(1) 105
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Histological modifications (eg, change in synaptic density)
associated with cognitive performance or learning have been
indirectly demonstrated with MEG in elite cello players
compared to music lovers or to controls without music training
(Pantev et al 1998). This very partial list offers a few arguments
favoring a distributed anatomy of cognition (cross-talks
between these structures).
Neurochemistry
Neurochemistry, although difficult to measure in humans,
provides clear proof of the organic nature of cognition,
offering attractive targets for designing new compounds.
Technological advances, eg, specific ligands with PET-scan,
experimental models in rodents or primates, in vivo access
to neurotransmitters, cerebral metabolism etc, are crucial for
targeting drugs to correct for neurochemical anomalies. All
of these techniques have their specific limitations and
uncertainties explaining why only a few cognitive functions
(memory, orientation, attention, decision making, speed of
data processing, learning) and rare neurotransmission systems
(acetylcholine [ACh], dopamine [DA], GABA, glutamate) and
their respective receptors are accessible in humans.
Consequently, cognitive pharmacology is limited at the
present time to drugs affecting the aminergic (antipsychotics,
antiparkinsonians, psychostimulants, drugs such as cocaine),
GABAergic (anxiolytics), and cholinergic (cholinesterase
inhibitors, nicotine agonists) systems and substances
activating neuronal metabolism (nootropic agents,
vasodilators and brain oxygenators) (Lynch 2002; Lockhart
and Lestage 2003; Higgins et al 2004; Lynch 2004; Mehlman
2004; Newhouse et al 2004). Collected pharmacological data
have nevertheless greatly improved our knowledge of
fundamental neurobiology and thus have provided
supplementary proof in favor of the biological basis of
cognitive mechanisms. ACh and DA remain for the time being
the two most illustrative examples of the therapeutic approach
(Muir 1997; Previc 1999; Southwick et al 2002; Higgins et al
2004) even though peptides, insulin, melatonin or estrogens
offer new perspectives (Delagrange and Guardiola-Lemaître
1997; Craft et al 1999; Dubal et al 1999). Steroid hormones
clearly modify CNS function as demonstrated by the analysis
of the neuropsychiatric correlations observed during the
perimenopause period (Feld et al 2005). Cholesterol has
recently been at the forefront line of potential cognition-
modifiers, any modification of its metabolism, for instance by
the statins, having an impact on membrane integrity and intra-
neuronal signaling and hence cognitive performance (Xiong
et al 2005). In addition, proteins (β-amyloid and tau proteins)
are involved in the memory deficit of AD leading to complex
changes in our vision of the biological mechanisms of
memory (SantaCruz et al 2005; Lesné et al 2006) and further
lengthening the list of compounds implicated in the
machinery of memory (Miyashita 2004). When considering
the neurobiological targets which, in the near future, could
be accessible for drugs (Vakalopoulos 2006; Nichols and
Newsome 1999), glutamate and its different receptors,
notably NMDA, AMPA or metabotropic glutamate 5
(mGluR5) receptors, appear as excellent candidates
(Robbins and Murphy 2006) more precisely in the domain
of learning and retrieval (Riedel et al 2003); the role of
glutamate in cytotoxicity amplifies the interest of the
pharmacology of this system in the neurodegenerative
diseases where cognitive impairment is at the forefront.
Neurogenetics
Although at the present time out of the scope of human
therapeutics, the genetic basis of cognition and of general
cognitive ability appears to be a fascinating approach (Flint
1999; Plomin 1999) for the teams involved in drug discovery.
Different genes have been pointed out in different situations
from AD (presenilins, apolipoprotein E), dyslexia (chromosome
6) to schizophrenia associated with a pronounced learning
deficit (Sanderson et al 1999). Williams syndrome, which is
a rare neurogenetic developmental disorder, is a paradigm
linking a profound cognitive impairment to a deletion on
chromosome band 7q11.23 (Bellugi et al 1999; Levitin 2005).
According to Payton (2006) potential pharmacological
advantages may be procured from the study of cognitive
genetics.
Obstacles facing cognitive
pharmacology
Despite the high prevalence of cognitive disorders and the
disastrous consequences in terms of individual independence
and social and familial relations, health authorities in almost
all countries of the world have failed to officially recognize
the beneficial effects of cognitive drug therapy outside the
realm of symptomatic treatment for AD. Thus, from a
regulatory point of view, cognitive pharmacology is limited
to three cholinesterase inhibitors (donepezil, rivastigmine,
galantamine) and one modulator of glutamate transmission
(memantine) (Allain and Bentué-Ferrer 2003). Cognitive and
concentration-attention disorders thus remain orphan
symptoms even when they occur as part of an identifiedNeuropsychiatric Disease and Treatment 2007:3(1) 106
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condition (parkinsonism, non-AD dementia, depression, post-
traumatic stress disorder, schizophrenia) or are the sole
expression of an identified cerebral dysfunction (post-
ischemia sequela, head trauma, neurogenetic disease).
One of the explanations probably lies in the methodological
difficulties inherent in the development of “ pro-cognitive”
drugs, the main problems including: 1) transposition of a
subjective complaint into an objective measurement of
performance; 2) the apparent benign nature of the disorder
considering the age of the individual; 3) changing classification
systems and nosographic considerations (for example, the
concept of Age Associated Memory Impairment (AAMI) has
changed greatly over the last fifteen years evolving into Age
Related Cognitive Disorder (ARCD) then later Mild Cognitive
Impairment (MCI), even more recently questioned by Fernandez
et al (2005); 4) inadequate and insufficiently sensitive
measurement tools for studying cognitive function; 5) the
excessively global or composite nature of commonly used
evaluation scales; 6) limited therapeutic effects which, moreover,
could fade out with time; 7) current debate opposing etiological
and symptomatic treatments. In addition to these problems, there
is the question, perhaps more psychological than regulatory, of
priorities. For example, when associated with another disease,
cognitive impairment is often considered a secondary
therapeutic objective (memory impairment in Parkinson’s
disease or fatigue in multiple sclerosis). Inversely, the risk of
deleterious effects on cognition may become the unique
consideration when examining certain drugs or drug classes.
The example of psychotropics, particularly benzodiazepines, is
particularly illustrative since this class of drugs has been
associated with memory impairment. The same type of thinking
leads to the idea that use of a given compound should be
restricted to a given disease and not for pathological conditions
occurring within different diseases (cholinesterase inhibitors
for example have proven efficacy for cognitive disorders in
several diseases such as AD or PD or even attention disorders in
children). This type of discordance between regulatory
guidelines and proven efficacy necessarily leads to prescriptions
outside officially approved indications.
Faced with this dominant attitude of international
regulatory authorities, the pharmaceutical industry appears
to be gradually slipping away from the objective of developing
products which could provide purely symptomatic improve-
ment for the different components of cognition. The fear is
that such symptomatic drugs could be sidetracked from their
intended use, as has been observed with psychostimulants
(ie, amphetamines), producing a negative impact on the drug
development project. This fear is widespread and further
exacerbated by the fact that many members of this hetero-
geneous group of pharmacotherapeutic agents (“cognitive
stimulants”, neuron metabolism activators, nootropics) are
no longer reimbursed by the French health care fund or have
simply been struck off the pharmacopoeia (Mehlman 2004).
The current orientation in the pharmaceutical industry is to
direct research towards products with more pathophysiological
actions, contributing to progress in the concepts of
neurocytoprotection and neuroregeneration, at least within
the framework of the main neurodegenerative diseases such
as AD (Akwa et al 2005) or PD.
In spite of the long-term efforts and initiative of the
Nationale Institute of Heath (NIH) in the USA to develop
cognitive pharmacology (Cutler et al 1985), the National
Institute for Health and Clinical Excellence (NICE) in UK,
recently reappraised the cost-effectiveness ratio of anti-
dementia drugs in a rather critical, controversial and negative
way; the debate again cast some shadow over this category
of compounds.
Studies in healthy volunteers
A compound’s impact on human cognition is determined
from laboratory tests. The procedure is well controlled and
standardized: specific test batteries (Table 2) performed by
the same subject, according to cross-over designs, clearly
lead to the assessment of the compound’s effect on the
different components of cognitive functions. Several test
batteries are available and commonly used in clinical
pharmacology; the comparative advantages or caveats of
those procedures are beyond the scope of the review; the
question will be either to cover the main cognitive functions
performances (Table 2) or rather to deeply analyze the different
components of a specific function, such as the different types
of memory. Tests are comparative using different doses, with
the initial objective of determining the relative safety of the
compound under study. It is important to recall that such
work, which establishes the “cognitive map” of a given drug,
with a detailed description of its effects on given “intellectual”
functions, is conducted with healthy volunteers.
Beyond this standard approach, the current objectives of
laboratory studies have been broadened to try to demonstrate
the real beneficial effect of drugs on cognition. This is a new
approach to clinical pharmacology with the goal of developing
new treatments for a wide range of indications accompanied
by cognitive disturbances: pathological brain aging,
dementia (neurodegenerative disease, vascular or HIV-relatedNeuropsychiatric Disease and Treatment 2007:3(1) 107
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dementia), the major psychiatric syndromes and the
consequences of head trauma.
In order to ascertain the specific effects of a given
drug (psychotropics, psychostimulants, anti-hypertensives,
anti-histaminics) on brain processes, early phase trials must
comply with standard controlled and validated methodologies.
Trials must be conducted in certified laboratories using
double-blind experimental protocols versus placebo and a
reference product (substances with well-known effects:
caffeine, benzodiazepine, amphetamine, clonidine), in young
or older healthy volunteers (for certain tasks, it may be useful
to have volunteers with a diminished baseline performance in
order to facilitate demonstration of the pharmacological
activity and avoid the floor or ceiling effects). The different
evaluation criteria require experienced observers to produce
valid information. Results must be interpreted with due
precautions. Measurements of a given parameter, for example,
depend on the degree of motivation or on changes in strategy
as well as test-induced fatigue. For each compound evaluated,
the risk-benefit ratio can be expressed by the formula I: NI,
where I is the number of tests with a significant change in
performance score and NI the number of tests with result
Table 2  Measures of performance in clinical pharmacology
A – Psychomotor performance Actual car driving
Simulated car driving
Simulated car tracking
B – Sensorimotor coordination speed Adaptive tracking
Critical tracking
Continuous tracking
Visuo-motor coordination
Choice reaction time
Simple reaction time
Reaction time
Pursuit rotor
C – CNS arousal, information processing Critical flicker fusion
Digit symbol substitution task
Mental arithmetic
Letter cancellation
Stroop color test
Logical reasoning
Visual search task
D – Memory Short-term memory
Continuous memory task
E – Sensory skills  Vigilance task
Attention task
Continuous attention task
Dynamic visual acuity
Simulated assembly-like task
F – Motor ability Finger tapping
G – Physiology Electroencephalography (EEG)
Continuous EEG
Multiple sleep latency test
Evoked potentials
Actigraphy
H – Subjective ratings Visual analogue rating scales
Profile of moods scale
Stanford sleepiness scale
Note: From Hindmarch and Shamsi (1999).Neuropsychiatric Disease and Treatment 2007:3(1) 108
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scores not different from placebo (Hindmarch and Shamsi
1999). When pharmacokinetic studies are associated, it is
possible to link the psychomotor or cognitive effect
mathematically to usual kinetic parameters (search for optimal
dose and pharmacokinetic-pharmacodynamic modeling [PK/
PD studies]). The results obtained in a small number of healthy
volunteers are reliable (the disease effect is absent as are
cotherapies usually observed in patients) and can be
extrapolated to patients in a therapeutic situation; here the
exercise will consist in comparing those laboratory studies
with the results obtained, with the same drugs, either in the
large scale phase III studies or in Pharmacovigilance surveys.
The cognitive map thus obtained enables a surmise of more
overall and behavioral effects, in patients. For clinical
research, ligands specific for certain CNS receptors enable
assigning a specific (or selective) role to certain receptors or
neurotransmission circuits during a specific phase of data
processing in the CNS. As mentioned above, this enables
linking data collected from animal models to those observed
in human volunteers. The example of the dopaminergic
systems is instructive here, since relatively specific agonist
and antagonist agents are identified for each of the five
subtypes of receptors. In their work with quinpirole, a specific
dopaminergic D2 agonist, Arnsten et al (1995) demonstrated
in the monkey that these receptors are implicated in higher
cognitive functions such as memory tasks with delayed recall.
This observation demonstrated in particular the importance
of dosage. Small doses produced a deleterious effect by action
on presynaptic autoreceptors altering the animals’ performance
while high doses on the contrary stimulated postsynaptic
receptors improving the same paradigms. It was also
instructive to use older monkeys which demonstrated an age-
related alteration in the dopaminergic systems with a prefrontal
projection and also explained that the deleterious effect of
small doses was attenuated or absent, demonstrating probably
altered presynaptic structures in these older animals. Other
experimental work supported the hypothesis of a role of DA
in the function of the prefrontal cerebral cortex (cortical D1
receptors for example determining the performance on a
working memory task) (Nieoullon 2002). Similar results were
obtained in healthy volunteers. Servan-Schreiber et al (1998a, b)
provided an elegant demonstration that administration of d-
amphetamine (0.25 mg/kg per os) improves information
processing in the brain via dopaminergic transmission, and
that the accuracy of complex tasks are improved (probably
through improved attention mechanisms) without modifying
vigilance. Similarly, recent work by Volkow et al (2000) in
healthy volunteers demonstrated a correlation between age-
related dopaminergic activity and performance on different
neuropsychological tests. These results provide supplementary
proof of the role of the dopaminergic system in cognitive
disorders in the elderly subject. Curiously, few studies have
been published on available dopaminergic agonists other
than piribedil, a D1, D2, and D3 agonist (Schück et al 2002)
and apomorphine, a D1 and D2 agonist (Luthringer et al 1999;
Manfredi et al 1998). These data demonstrate a pro-cognitive
and awakening effect of these dopamine agonists (increased
beta activity on the EEG, improved delayed recall). These
results opened an interesting discussion concerning the
attribution of narcolepsy attacks in traffic accident victims
(Frucht et al 1999) to ropinirole (D2 agonist similar to
quinpirole mentioned above) and pramipexole (D2, D3, D4
agonist). Several pharmacological classes have been analyzed
using the cognitive mapping method mentioned above. This
should contribute to better definition of their risk-benefit
ratio and their potential indications: nicotine, caffeine,
antihistaminics, hypnotics, anxiolytics, antipsychotics
(Allain et al 2000a; Gandon and Allain 2002; Patat et al
1996; Patat 2000; Stip et al 1999). In all likelihood, the list
of the drugs to be tested according to such a procedure will
continue to lengthen for three reasons: 1) sudden increase in
the number of drugs available in neurology, 2) overt policy
to treat several orphan conditions of the CNS (most of which
are dominated by cognitive disorders), 3) worries about drug
safety for cognition (Cognitive Pharmacovigilance).
Drugs and memory
Drugs for Alzheimer’s disease
Several cholinesterase inhibitors (donepezil, rivastigmine,
galantamine) and one glutamatergic neurotransmission
modulator (memantine) are officially recognized as beneficial
for patients with AD. These compounds were awarded
marketing approval on the basis of improved scores on global
scales measuring overall cognitive decline and its impact on
daily living, and not because of a positive effect on specific
memory tests (Lane et al 2006). Such targeted tests would
have to exhibit a clear effect before these drugs could be used
for MCI (at least for amnestic-MCI, as still controversially
considered to be an isolated memory disorder probably
announcing AD). Recent studies of cholinesterase inhibitors
in MCI have been unable to demonstrate any beneficial
effects in terms of symptomatic improvement on memory
tests (Allain et al 2004), nor any preventive effect onNeuropsychiatric Disease and Treatment 2007:3(1) 109
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conversion to AD (Petersen et al 2005). These negative results,
although partially explainable (for instance upregulation of
cholinergic systems at the early phase of the disease) continue
to discredit the cholinesterase inhibitor class of drugs
(Kaduszkiewicz et al 2005).
Antioxidants
At very high doses, vitamin E (tocopherol) does not have
any direct effect on memory but it appears to retard by a few
months progression to AD and might be helpful for the
prevention of other forms of dementia in healthy subjects.
Similar results have been obtained with selegiline, a MAO-B
(monoamine oxidase type B) inhibitor whose impact on DA
concentrations could also have a symptomatic effect by
stimulating dopaminergic tone.
Antioxidants, which counteract the deleterious effect of
free radicals, cannot be considered as pro-memory drugs per
se. They have however opened new avenues of very active
research in the field of neuroprotective agents, reflecting the
fragile nature of human memory and its vulnerability to
aggression (age, depression, anxiety, ischemia-hypoxia,
addiction, HIV-related dementia).
Anti-aging drugs
In many countries, a variety of medications are marketed and
prescribed for age-related cognitive decline. These old drugs
(vasodilators, brain oxygenators, nootropics, cognitive
enhancers) (Riedel and Jolles 1996) have been used for years
without either formal proof of efficacy in dementia or showing
a small effect-size. Aging being a normal physiological
process, there is no clear indication for their use. These drugs
do however have pharmacological properties quite in line
with the multifactorial disseminated nature of memory
disorders: membrane fluidification, activation of neuronal
energy metabolism, arousal. A few old studies highlight a
facilitating effect on memory which might be worth
evaluating with modern methodology.
Estrogens
There is a growing body of evidence supporting the notion
that estrogens have an impact on memory processes in women
(Bentué-Ferrer et al 1999). Much work has demonstrated that
menopausal women taking synthetic estrogens in hormone
substitutive therapy exhibit better results on memory tests
than those not on replacement therapy (Matthews et al 1999;
Steffens et al 1999). Conversely, the recent Women’s Health
Initiative Memory Study which included 4532 menopausal
women aged 65 years or more, found that long-term hormone
replacement therapy with synthetic steroid hormones,
estrogen and progesterone, increased the risk of probable
dementia and did not prevent MCI (Shumaker et al 2003).
The debate remains open regarding the beneficial effect of
natural or synthetic oestrogens, respectively, on memory in
menopausal women (Henderson et al 2003; Sherwin 2005).
Natural substances
A short list of natural substances with a recognized effect on
memory performance is presented in Table 3. These compounds,
often found in foodstuffs (caffeine, glucose, nicotine), cannot
be proposed without the necessary precautions but can
greatly contribute to targeted research on the possible impact
of future promnestic drugs. This opens new perspectives for a
more mechanistic approach to the cellular signaling pathways
of memory, for example with the use of phosphodiesterase IV
inhibitors increasing CREB phosphorylation (Nagakura et
al 2002; Tully et al 2003). New drugs obtained from plant
extracts have also received marketing approval, for example
Paullinia cupana (Kennedy et al 2004) or more recently
huperzine, extracted from a lycopod species growing in China
(Lycopodium serratum) and galantamine, extracted from
snowdrop (Galanthus nivalis), both indicated for AD (Zangara
2003; Brodaty et al 2005).
Over-the-counter drugs promoted as memory aids cannot
be ignored. These drugs most of the time are used as
automedication and should be more extensively studied
either to clearly demonstrate a significant clinical benefit or
to establish their safety profile.
Drug safety and memory
When looking at the pharmacovigilance data, it is important to
take into account the sources of information as well as the study
conditions and the manner the drug is used. For example, in the
treatment of anxiety, benzodiazepines (enhancers of
GABAergic neurotransmission), can greatly alter recall after
an acute administration, whereas following a chronic
treatment, no memory impairment seems to occur, due to a
tolerance phenomena (Curran 1991, 1992). This point raises
a supplementary problem since most psychiatric diseases
(depression, anxiety and schizophrenia) are associated with
cognitive disorders often affecting memory, even before any
treatment. Psychotropics alleviate many of these disorders.
But could their final effects, by possible analogy with work
on beta-blockers used for the treatment of posttraumatic stress
disorder (Giles 2005; Van Stegeren et al 2002), result from theirNeuropsychiatric Disease and Treatment 2007:3(1) 110
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amnesic action, helping the patient “forget” distressing
memories? It is also important to recall that all compounds with
anti-cholinergic effects (tricyclic antidepressants, urological
drugs) perturb memory function, mimicking the scopolamine
effect used for inducing experimental amnesia (Mintzer and
Griffiths 2003; Parra 2003). The impact of these different agents
on cognition and memory has to be re-evaluated in the early
phases of the disease, in the light of new advances in
neuropsychopharmacology. Schematically, new compounds
designed for long-term treatments (Z compounds: zopiclone,
zolpidem, zaleplon) (Terzano et al 2003; Allain et al 2005),
serotonine reuptake inhibitors, antipsychotics (Brunnauer et al
2004) or anticonvulsants do not alter cognition or memory when
prescribed at therapeutic doses. Though deleterious effects on
memory per se are sometimes difficult to distinguish from
other cognitive disorders or from negative impact on vigilance
of numerous common drugs (antihistamininics, beta-blockers,
illicit drugs including cannabis and 3, 4-
methylenedioxymethamphetamine [ecstasy]); drug registries
of substances-induced memory impairment provide a rich
source of information (Patat 2000; Dafters et al 2004).
Drugs and language
Historical background
The idea that drugs can be used to correct for altered language
capacity is not new. As early as 1947, Linn (1947) tested
sodium amytal in a woman with ischemic aphasia,
hypothesizing a reduction in the “frustration and inhibition
of communication” characteristic of aphasia. Unfortunately,
the effect could not be confirmed in a group of 27 patients
treated by Bergman and Green (1951) in 1951. Although
these early studies did initiate a new domain that could be
named “pharmacolinguistics”, with the development of the
first psychotropic drugs in the 1960s and 1970s (meprobamate,
chlordiazepoxide, methylphenidate) generally, little real
progress was made. Since most cases of aphasia occur
secondary to stroke, the main objective of subsequent studies
was focused on stroke-related mechanisms, with little work
directly devoted to language disorders themselves. Even in a
most recent review by Shisler et al (2000), and despite the
provocative title of “Pharmacological approaches to the
treatment and prevention of aphasia”, the discussion was
limited to drugs affecting the brain ischemic processes
(glutamate modulators, protein kinase C inhibitors,
monoganglioside, calcium channel inhibitors, free radical
scavengers, and thrombolytic drugs). Not surprisingly, most
of the highly interesting work on language disorders (or
degenerative diseases like semantic dementia) and drugs has
been reported by rehabilitation specialists (Musso et al 1999).
Brain oxygenation
The effect of hyperbaric oxygen therapy has been widely
studied, and certain reports have used evaluation criteria
clearly belonging to the domain of language (Sarno 1969;
Sarno et al 1972) including the Functional Communication
Table 3  Natural substances for memory performance
Compound Proven effects Comments Reference
on memory
Glucose + Acetylcholine synthesis Hoyer 2003
Neuronal metabolism
Cerebral plasticity
Nicotine + Effects similar to donepezil for piloting
performance
Indirect effects on glutamatergic, Picciotto 2003
GABAergic, dopaminergic, nicotinic Mumenthaler et al 2003
(α6, α7, α4β2 and β3) receptors
Desensitization of nicotinic receptors
Caffeine + Antagonist of adenosine (A1) receptors
facilitating memory and arousal Ribeiro et al 2002
Role in cerebral neurotransmission
homeostasis
Plant extracts: ginkgo, + Used in traditional medicine, they might Ernst 2002
echinacea, kava treat memory disorders Howes et al 2003Neuropsychiatric Disease and Treatment 2007:3(1) 111
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Profile, the Token Test or subsets of the Wechsler Adult
Intelligence Scale (WAIS). But it was rapidly recognized that
this approach was devoid of any therapeutic benefit. During
this period, different groups of drugs, called vasodilators or
brain oxygenators, were tested, with the mechanistic
hypothesis that they might help restore function in ischemic
brain areas. In 1951, Smith and Turton (1951) described very
clear improvement in verbal fluency, elocution and
“loquacity” in a patient given 40 mg tolazoline after
development of an aphasia secondary to stroke. Piracetam, a
nootropic agonist of GABAergic transmission also improving
oxygen brain bioavailability, given at the dose of 4.8 g/d, has
also been found to significantly improve language function
in several studies with acceptable methodologies (Huber et al
1997). Other brain oxygenators, such as vincamine or almitrine-
raubasine (Enderby et al 1994) can improve elocution and
quality of language in “vascular” patients (stroke, dementia)
although the linguistic items used for evaluation lacked
precision and were buried among other elements in composite
evaluation scales. The recent identification of neuroglobulin,
a protein that transports oxygen from the blood stream to
neurons much like myoglobulin in muscles, has recently given
new impetus to the oxygen theory (Burmester et al 2000) and
to the compounds able to improve brain oxygen availability;
apparently this approach did not lead to any real progress in
the field of pharmacolinguistics.
Catecholamines
Amphetamine, a noradrenergic and dopaminergic stimulant,
has been studied in Broca’s aphasia in a princeps case
reported by Walker-Batson et al (1990). The positive effect
obtained in this unique patient persisted for 12 months and
led to further studies that provided less convincing results,
particularly since amphetamine was associated with classical
language rehabilitation therapy and the studies were not
double-blinded (Hassid 1995; Walker-Batson et al 1995).
Likewise bromocriptine, a direct dopamine agonist, has
been widely studied. In one case described by Albert et al
(1988), objective improvement in the Boston Diagnostic
Aphasia Examination persisted for one month even though
conversational fluency did not appear to be modified.
Unfortunately, except for the studies by Gupta and Mlcoch
(1992) who used 10 and 30 mg/day, and by Sabe et al (1992)
who used 15 and 60 mg/day, the different reports to date,
which have used methodologies of more or less satisfactory
quality, have been unable to provide objective evidence of
any gain in linguistic performance in a variety of aphasic
patients (Sabe et al 1995). This work has nevertheless rightfully
raised the question of the role of DA and the subcortical
structures in cognition and language (Cohen and Kegl 1999;
Crosson 1999). To our knowledge, the new more specific
dopaminergic agonists have not been studied in the
“indication” of aphasia, although their impact on language,
and even their beneficial effect on other cognitive functions,
has been demonstrated.
Cholinergic drugs
According to Small (1994), drugs targeting cholinergic
systems have demonstrated a disappointing effect on
language and language disorders. Use of cholinesterase
inhibitors in the treatment of AD has triggered new debate,
but the “aphasia” element remains again just one of the
symptoms observed in this degenerative disease, in addition
to inaugural and predominant memory disorders. Jacobs
et al (1996) have described the beneficial effect of increased
brain concentrations of ACh on anomia, correlatively with
Tanaka et al (1997) who worked with aphasia patients. The
recent case reported by Hughes et al (2000) where adynamic
aphasia was related to a subcortical (thalamus-internal
capsule) lacuna is instructive: first of all, donepezil, a
cholinesterase inhibitor, clearly improved linguistic
performance (verbal fluency), and secondly, the benefit
persisted beyond treatment withdrawal, raising the question
of the role of brain neuroplasticity (Allain et al 1997; Neville
and Bavelier 1998) and its cholinergic dependence in
language recovery. It is quite difficult to determine the effect
of cholinesterase inhibitors (tacrine, donepezil, rivastigmine,
galantamine) (Bentué-Ferrer et al 2001) on language and
linguistics among the results of phase III trials in dementia
that contributed to their marketing approval. Regulatory
guidelines were very strict (Allain et al 1998) and the
“cognitive” scales (ADAS-Cog, MMS, CGI, GDS) used for
assessment contained few linguistic items, despite the
frequency and importance of disorders of language
comprehension and expression in patients with AD (Grossman
et al 1996; Grossman et al 1998).
The effect of ACh (cholinergic agonists and pro-
cholinergic drugs) on language may be direct or indirect, but
involves two types of central receptors, muscarinic and
nicotinic receptors, that beyond language mediate essential
cognitive functions in the human brain (Levin and Simon
1998; Jones et al 1999; Paterson and Nordberg 2000;
Picciotto et al 2000; Picciotto 2003). In the same line of
thinking, few data are available on tolerance of drugs
potentially deleterious for language and linguistics.Neuropsychiatric Disease and Treatment 2007:3(1) 112
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As a whole, at the present time, no recognized drug can be
clearly recommended as an activator or corrector of language
in human disease.
Drugs and attention
Attention, as opposed to distraction, involves a sorting process
in the planning of a response and thus controls executive
functions. Attention processes extract pertinent signals from
background noise. They must be distinguished from processes
underlying vigilance (arousal) and to a lesser degree working
memory. Attention disorders are the correlate of several
neuropsychiatric diseases (Berger and Posner 2000) and are in
the forefront in AD (Calderon et al 2001), generalized anxiety
disease (GAD), schizophrenia, and in attention-deficit-
hyperactivity disorder (ADHD) (Elia et al 1999). Attention
disorders, irrespective of the severity, have an impact on other
cognitive functions (memory and learning, for example) and
most importantly potentially perturb execution of daily
activities and skills. As emphasized above, anatomical correlates
of these processes are known (Fernandez-Duque and Posner
2001; Filley 2002; Raz 2004; Shipp 2004). The psychological
mechanisms underlying this function have been described and
studied in detail (Awh and Jonides 2001; Cowan et al 2005;
Hester and Garavan 2005) enabling the development of tests
and procedures for analyzing attention performance in humans
(Driver and Frackowiak 2001; Oberauer 2002; Oades et al 2005).
These methods are used in clinical pharmacology (Stroop test,
continuous performance test, critical tracking task). The
neurochemical basis of these functions, mainly neuro-
transmitters, has also been deciphered so that ACh, amines and
glutamate have become selective targets for drugs designed to
improve attention and concentration (Coull 1998; Posner and
Driver 1992). Paradoxically, the pharmacology of attention
disorders has not been developed extensively (Allain et al 2000b)
outside the field of ADHD in children where three psycho-
stimulants with aminergic action (amphetamine, atomoxetine,
methylphenidate) have been officially recognized as effective
(Elia et al 1999; Leonard et al 2004). Neurochemistry has led to
numerous publications in animal models (mainly with rodents)
which, using specific ligands, demonstrate the action of
dopaminergic D1 (Nieoullon 2002), adrenergic α2 (Franowicz et al
2002), and cholinergic nicotinic (nAChR) (Levin and Simon 1998;
Hahn et al 2003) receptors, all involved in attention/concentration
performance. These receptors could legitimately become priority
targets for “pro-attention” drugs in humans. This has been
corroborated in clinical pharmacology with drugs used for other
indications: guanfacine, a central antihypertensive agent and
agonist of adrenoceptors α2A (Jakala et al 1999), bupropion, an
inhibitor of DA and noradrenaline reuptake indicated for smoking
cessation (Wilens et al 2005), piribedil and pramipexole,
antiparkinson D2 and D3 agonists (Schück et al 2002; Peretti et al
2004). The most widely studied compounds at the present time
are nAChR agonists such as ABT-418 and ABT-089 (Prendergast
et al 1998); due to the large number of nAChR subtypes in the
CNS, a specific function and the capacity of inducing tolerance
or not have to be determined for each ligand. Most likely,
cholinesterase inhibitors principally act on attention/
concentration by reinforcing the cholinergic tone on the
nAChR. Data from humans are however greatly dominated
by the search for a deleterious effect on attention, both for
psychotropics and illicit drugs (Allain et al 2000a; Patat
2000).
More generally, and beyond the notion of ADHD, attention
disorders could be improved by effective drugs currently in the
authorization process and awaiting pertinent clinical trials.
Broader indications could be outlined, beyond military
applications or situations where sustained attention is of prime
importance (competition sports, civil aviation, surgery, computer
work).
Perspectives–conclusion
The data from literature described here on memory, language,
and attention/concentration show that it is too early to try to
codify pharmacological strategies for the impairment of these
cognitive functions in adult human beings. Despite the recent
emergence of cognitive neurosciences (Friederici and
Ungerleider 2005) and the development of specific
evaluation tools for the different components of cognition
in humans, cognitive pharmacology remains in the
exploratory phase, with neurobiological concepts that still
need to be validated. The fact that cognitive function is never
proposed as a major evaluation criterion for large-scale studies
or epidemiology clearly illustrates this situation. The data
which are available come from pharmacovigilance studies,
enabling an evidence-based choice between drugs of a given
class (ie, psychotropics) as a function of observed deleterious
effects on different components of cognition (for example
anxiolytics and antipsychotics for the treatment of agitation
in the demented subject). The only drugs with evidence-based
indications are used in AD, mainly cholinesterase inhibitors,
because of their proven beneficial impact on working memory
and attention. Extension of their indications to cognitive
disorders associated with vascular dementia (Allain et al
2003), PD (Emre et al 2004), or Lewy body dementia is
legitimate. Theoretically, cognitive stimulants and nootropics
which have a more global action on neuronal metabolism,Neuropsychiatric Disease and Treatment 2007:3(1) 113
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membrane fluidity, and the rate of information processing could
be used for a variety of conditions involving altered cognition
or attention. Unfortunately, the large number of trials
conducted with these compounds has been unsuccessful in
convincing the public health authorities. While waiting for
products with proven etiopathogenic efficacy (Akwa et al 2005),
an alternative therapeutic strategy would be to promote
specific symptom relief in a complex disease such as AD,
schizophrenia or Huntington’s diseases.
To meet the challenges of further development of
cognitive pharmacology, there are three requisites: 1)
promote large-scale clinical trials centered on cognition in a
variety of nosographic entities (Huntington’s disease,
posttraumatic stress disorder, psychoses, head trauma, stroke);
2) encourage new explorations in neurobiology and
proteomics; 3) broaden the scope of pharmacological
improvement of cognitive and intellectual functions (eg,
choice, decision, perception of time [Vanneste and Pouthas
1999]). This pharmacological and therapeutic approach
should enable improvement for a large number of adults
suffering socially and professionally from cognitive
impairment.
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